Cargando…
Genomics driven-oncology: challenges and perspectives
Molecularly defined subgroups of tumors characterized by specific driver mutations have been identified in the majority of cancers. The availability of novel drugs capable of targeting signaling pathways activated by genetic derangements has led to hypothesize the possibility to treat patients based...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381449/ https://www.ncbi.nlm.nih.gov/pubmed/25884512 http://dx.doi.org/10.1186/s12885-015-1147-7 |
_version_ | 1782364455255932928 |
---|---|
author | Normanno, Nicola Cree, Ian A |
author_facet | Normanno, Nicola Cree, Ian A |
author_sort | Normanno, Nicola |
collection | PubMed |
description | Molecularly defined subgroups of tumors characterized by specific driver mutations have been identified in the majority of cancers. The availability of novel drugs capable of targeting signaling pathways activated by genetic derangements has led to hypothesize the possibility to treat patients based on their genomic profile. A clear example is represented by lung adenocarcinoma for which it has been possible to identify driver genetic alterations in approximately 75% of the cases. Among these, RET fusion transcripts are detectable in about 1–2% of lung adenocarcinomas and might represent targets for therapeutic intervention with RET kinase inhibitors. However, a number of issues need to be addressed to make genomics-driven oncology routinely accessible for cancer patients, including: 1) the availability of novel methods in molecular diagnostics that allow a comprehensive molecular characterization of lung tumors starting from a low input DNA/RNA; 2) identification of reliable and reproducible biomarkers of response/resistance to targeted agents; 3) the assessment of the role of tumor heterogeneity in the response to drugs targeting molecular pathways. |
format | Online Article Text |
id | pubmed-4381449 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-43814492015-04-02 Genomics driven-oncology: challenges and perspectives Normanno, Nicola Cree, Ian A BMC Cancer Commentary Molecularly defined subgroups of tumors characterized by specific driver mutations have been identified in the majority of cancers. The availability of novel drugs capable of targeting signaling pathways activated by genetic derangements has led to hypothesize the possibility to treat patients based on their genomic profile. A clear example is represented by lung adenocarcinoma for which it has been possible to identify driver genetic alterations in approximately 75% of the cases. Among these, RET fusion transcripts are detectable in about 1–2% of lung adenocarcinomas and might represent targets for therapeutic intervention with RET kinase inhibitors. However, a number of issues need to be addressed to make genomics-driven oncology routinely accessible for cancer patients, including: 1) the availability of novel methods in molecular diagnostics that allow a comprehensive molecular characterization of lung tumors starting from a low input DNA/RNA; 2) identification of reliable and reproducible biomarkers of response/resistance to targeted agents; 3) the assessment of the role of tumor heterogeneity in the response to drugs targeting molecular pathways. BioMed Central 2015-03-23 /pmc/articles/PMC4381449/ /pubmed/25884512 http://dx.doi.org/10.1186/s12885-015-1147-7 Text en © Normanno and Cree; licensee BioMed Central. 2015 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Commentary Normanno, Nicola Cree, Ian A Genomics driven-oncology: challenges and perspectives |
title | Genomics driven-oncology: challenges and perspectives |
title_full | Genomics driven-oncology: challenges and perspectives |
title_fullStr | Genomics driven-oncology: challenges and perspectives |
title_full_unstemmed | Genomics driven-oncology: challenges and perspectives |
title_short | Genomics driven-oncology: challenges and perspectives |
title_sort | genomics driven-oncology: challenges and perspectives |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381449/ https://www.ncbi.nlm.nih.gov/pubmed/25884512 http://dx.doi.org/10.1186/s12885-015-1147-7 |
work_keys_str_mv | AT normannonicola genomicsdrivenoncologychallengesandperspectives AT creeiana genomicsdrivenoncologychallengesandperspectives |